Back to publications
Most-Favored- Nation’s Global Impact: The Future of Drug Pricing
Global pricing reform is no longer a distant risk—it’s a present reality. To thrive, life sciences leaders must reimagine value through an integrated lens of policy foresight, data-driven access, and cross-market agility.
Get the full report
A New Global Equation for Pharma Market Access Leaders
The new Most-Favored-Nation (MFN) regulation in the U.S. is poised to reshape the global drug pricing landscape.
In the report “Most-Favored-Nation’s Global Impact: The Future of Drug Pricing”, we examine how this regulation could shift the balance between the U.S. and Europe, exert downward pressure on drug prices, and accelerate the adoption of outcome-based pricing models worldwide.
Want to read the full white paper?
Enter your data to download the document